Toggle light / dark theme

Environmentalism and climate change are increasingly being pushed on us everywhere, and I wanted to write the transhumanism and life extension counter argument on why I prefer new technology over nature and sustainability. Here’s my new article:


On a warming planet bearing scars of significant environmental destruction, you’d think one of the 21st Century’s most notable emerging social groups—transhumanists—would be concerned. Many are not. Transhumanists first and foremost want to live indefinitely, and they are outraged at the fact their bodies age and are destined to die. They blame their biological nature, and dream of a day when DNA is replaced with silicon and data.

Their enmity of biology goes further than just their bodies. They see Mother Earth as a hostile space where every living creature—be it a tree, insect, mammal, or virus—is out for itself. Everything is part of the food chain, and subject to natural law: consumption by violent murder in the preponderance of cases. Life is vicious. It makes me think of pet dogs and cats, and how it’s reported they sometimes start eating their owner after they’ve died.

Many transhumanists want to change all this. They want to rid their worlds of biology. They favor concrete, steel, and code. Where once biological evolution was necessary to create primates and then modern humans, conscious and directed evolution has replaced it. Planet Earth doesn’t need iniquitous natural selection. It needs premeditated moral algorithms conceived by logic that do the most good for the largest number of people. This is something that an AI will probably be better at than humans in less than two decade’s time.

This post has been updated.

We’ve all just barely forgotten about the great American lettuce contamination of 2018, in which we were forced to forgo romaine over Thanksgiving, and another E. coli outbreak has already hit. The Centers for Disease Control released a notice of an ongoing outbreak centralized around Kentucky earlier this month, but at the time they weren’t sure what foods were to blame for the 72 illnesses and eight hospitalizations. Nearly half of those infections were in Kentucky, with the rest in Tennessee, Georgia, Ohio, and Virginia.

On April 12 the CDC posted an update: 109 people have been sickened by E. coli so far (that the CDC is aware of), and cases have cropped up in a sixth state (Indiana). Seventeen people have gone to the hospital, but no deaths are reported at this time.

Read more

Cell-by-cell genetic analyses of developing brain tissues in neonatal mice and laboratory models of brain cancer allowed scientists to discover a molecular driver of the highly aggressive, deadly, and treatment-resistant brain cancer, glioblastoma.

Published findings in Cell Stem Cell describe how the single-cell analyses identified a subpopulation of cells critical to formation—the early primitive progenitor cells of oligodendrocyte cells, pri-OPC progenitors, according to Q. Richard Lu, Ph.D., lead investigator and Scientific Director of the Brain Tumor Center at Cincinnati Children’s Hospital Medical Center.

The data suggest that reprogramming of primitive oligodendrocyte progenitors into a stem-like state plays an important role in glioma initiation and progression. The researchers’ primary molecular target in the study, a protein called Zfp36l1, launches biological programs that mirror those of healthy early brain development in the mice, but instead help fuel brain cancer growth. The discovery presents an opportunity to find out if new therapeutic approaches can stop glioblastoma at its earliest stages of initial formation or recurrence, Lu said.

Read more

Researchers have identified ketamine-induced brain-related changes that are responsible for maintaining the remission of behaviors related to depression in mice—findings that may help researchers develop interventions that promote lasting remission of depression in humans. The study, funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health, appears in the journal Science.

Major is one of the most common mental disorders in the United States, with approximately 17.3 million adults experienced a major depressive episode in 2017. However, many of the neural changes underlying the transitions between active depression, remission, and depression re-occurrence remain unknown. Ketamine, a fast-acting antidepressant which relieves depressive symptoms in hours instead of weeks or longer, provides an opportunity for researchers to investigate the short- and long-term biological changes underlying these transitions.

“Ketamine is a potentially transformative treatment for depression, but one of the major challenges associated with this drug is sustaining recovery after the ,” said study author Conor Liston, M.D., Ph.D., of Weill Cornell Medicine, New York City.

Read more

Guest writer Dr. Asimina Pantazi gives her impressions of the recent Berlin Undoing Aging Conference from the point of view of someone working in research.


As a millennial with limited orientation abilities but expertise with digital tools, I used Google Maps to find the venue, fearing that I would have no data and would get lost in Berlin, only to find out that I was only a couple of meters away from to the venue entrance.

The Undoing Aging 2019 conference took place on May 28–30 at Umspannwerk Alexanderplatz: a multi-level industrial setting, with metal stairs, funky lights, and a balcony overlooking the minimal conference hall. This gave me my first positive vibes.

Aubrey de Grey of the SENS Research Foundation and Michael Greve of the Forever Healthy Foundation organized a three-day event that focused on the cellular and molecular repair of age-related damage in order to medically control aging. The conference brought together a diverse audience from all corners of the world: scientists, doctors, students, biotechs, startups, pharma, investors, the media, government representatives, policy makers, and anti-aging research enthusiasts; many of them were Russians, and their country was impressively represented there!

Announces the publication of a new open-access quarterly report: AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2019/Q1. Except for providing the analysis of 350 investors, 50 corporations and 150 companies operating in the field, the main events that took place in the industry from January to March 2019 are covered. The report also features the list of 30 leading R&D centers that provide important researches in the segment.

Link to the Report: https://www.ai-pharma.dka.global/quarter-1-2019

#AI #artificialintelligence #drugdiscovery

Read more

Presents its list of the top 30 FemTech Influencers, whose efforts in the FemTech Healthcare, FemTech Preventive Medicine and FemTech Longevity sectors have helped to grow the industry to its current state of maturity.

Jill Angelo genneve Elina Berglund Natural Cycles Starling Bank Tania Boler Elvie Ghela Boskovich Judith Campisi Adia Femtech Collective Dame Products EMBR Robin Starbuck Farmanfarmaian Cora Lifestyle Angie Lee Janet Lieberman Nuala Murphy Moment.Health Elena Mustatea Bold Health Anastasia Georgievskaya Haut.AI Maven Clinic THINX Nicole Shanahan Clearaccessip, Inc. Tammy Sun Ida Tin

Link to the Report: https://www.aginganalytics.com/femtech-healthcare-q1-2019

Read more